Stifel Analysts Bullish on Abeona Therapeutics, Set $21 Target Price
Wednesday, 29 May 2024, 17:36
Stifel Analysts Bullish on Abeona Therapeutics
In a recent report, Stifel analysts have shown optimism towards Abeona Therapeutics by assigning a 'buy' rating and a target price of $21.
Positive Outlook on Growth
The analysts believe in the growth potential of the company, which has led to this positive outlook.
Investors may consider this assessment when making decisions in the healthcare sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.